Quote this publication Share Print

ALIMTA (pemetrexed), antimetabolite

ONCOLOGY - Focus
Opinions on drugs - Posted on Jun 09 2016

Reason for request

Re-assessment of the improvement in actual benefit

Moderate clinical added value in first-line treatment of unresectable malignant pleural mesothelioma

  • ALIMTA has marketing authorisation, in combination with ciscplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
  • It is the standard treatment for this disease. 

 


Actual benefit

Important

-


Improvement in actual benefit

III (modéré)

-


Therapeutic use

-

Contact Us

Évaluation des médicaments